Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial

Circulation

Volumn 99, Issue 21, 1999, Pages 2720-2732

  Antman, Elliott M ^a   Giugliano, Robert P ^a   Gibson, C Michael ^b   McCabe, Carolyn H ^a   Coussement, Patrick ^c   Kleiman, Neal S ^d   Vahanian, Alec ^e   Adgey, A A Jennifer ^f   Menown, Ian ^f   Rupprecht, Hans Jürgen ^g   Van Der Wieken, R ^h   Ducas, John ⁱ   Scherer, Joel ^j   Anderson, Keaven ^k   Van De Werf, Frans ^c   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e HÔPITAL TENON   (France)

^f ROYAL VICTORIA HOSPITAL   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

ⁱ HEALTH SCIENCES CENTRE   (Canada)

^j ELI LILLY AND COMPANY   (United States)

^k CENTOCOR INC   (United States)

more..

Author keywords

Myocardial infarction; Platelet aggregation inhibitors; Platelets; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; STREPTOKINASE;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; ST SEGMENT ELEVATION; THROMBOCYTE; THROMBOCYTOPENIA;

EID: 0033152273     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.21.2720     Document Type: Article

References (42)

1. The GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
2. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri ST, Davis V, Gibson CM, Poole WK, Braunwald E, and the TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994;24:1602-1610.
3. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E, for the TIMI Investigators. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction(TIMI) Phase II Clinical Trial. J Am Coll Cardiol. 1995;26:900-907.
4. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, and the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 1990;82:781-791.
5. Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero L, Jang I-K, Holt R, Fallon JT, Collen D. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol. 1990;16:1728-1735.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
7. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.
8. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Theroux P. New antithrombotics. Chest. 1995;108:471S-485S.
9. Coller BS. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730-755.
10. Coller BS. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Artery Dis. 1992;3:1016-1029.
11. Davies CH, Ormerod OJM. Failed coronary thrombolysis. Lancet. 1998; 351:1191-1196.
12. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation. 1997;95:1755-1759.
13. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest. 1988;81:1284-1291.
14. Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79:920-928.
15. Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen DA. Chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb. 1993;13:1837-1842.
16. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ, for the EPIC Investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1996;77:1045-1051.
17. Miller JM, Ohman EM, Schildcrout JS, Smalling RW, Betriu A, Califf RM, Topol EJ. Survival benefit of abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO III trial. J Am Coll Cardiol. 1998;31:191A. Abstract.
18. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ. Randomized, placebo-controlled trial of platelet glyco-protein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734-741.
19. Muhlestein JB, Gomez MA, Karagounis LA, Anderson JL. "Rescue ReoPro": acute utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. Circulation. 1995;92(suppl I):I-607. Abstract.
20. Kleiman N, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol. 1993;22:381-389.
21. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
22. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E, for the TIMI 4 Study Group. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888.
23. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E, for the TIMI 5 investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cordiol. 1994;23:993-1003.
24. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
25. Neuhaus K-L, Feuerer W, Jeep-Teebe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1989;14: 1566-1569.
26. Wald A. Sequential Analysis. New York, NY: Dover Publications; 1947: 88-105.
27. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1988;77:142-150.
28. Owen J, Friedman KD, Grossmann BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue-plasminogen activator or streptokinase induces transient thrombin activity. Blood. 1988;72:616-620.
29. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1995;25:203-209.
30. Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990;322: 33-42.
31. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders; 1997:1184-1288.
32. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
33. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
34. Coller BS. Augmentation of thrombolysis with antiplatelet drugs: overview. Coron Artery Dis. 1996;6:911-914.
35. Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood. 1994;83: 1006-1016.
36. Carr ME Jr, Carr SL, Hantgan RR, Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost. 1995;73:499-505.
37. Collet JP, Mirshahi M, Mishal Z, Montalescot G, Soria C, Soria J. A possible benefit of ReoPro: modification of the clot structure. Thromb Haemost. 1997;(suppl):662. Abstract.
38. Mascelli MA, Marciniak SJ, Weisman HF, Jordan R. In vitro characterization of dethrombosis by abciximab (ReoPro). Thromb Haemost. 1997; (suppl):661. Abstract.
39. Ronner E, van Kesteren HAM, Zijnen P, Tebbe U, Molhoek P, Cuffie C, Veltri E, Lorenz T, Neuhaus K, Simoons ML. Combined therapy with streptokinase and Integrilin. J Am Coll Cardiol. 1998;31(suppl A):191 A.
40. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy R, Love TW, Braunwald E, and the TIMI 10A Investigators. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95:351-356.
41. den Heijer P, Vermeer F, Ambrosioni E, Sadowski Z, Lopez-Sendon JL, von Essen R, Beaufils P, Thadani U, Adgey J, Pierard L, Brinker J, Davies RF, Smalling RW, Wallentin L, Caspi A, Pangerl A, Trickett L, Hauck C, Henry D, Chew P. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation. 1998;98:2117-2125.
42. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.